Elsevier, Neuroimaging Clinics of North America, 2(21), p. 327-344
DOI: 10.1016/j.nic.2011.02.008
Full text: Download
Despite significant progress in stroke prevention and acute treatment, stroke remains a leading cause of death and adult morbidity worldwide. By defining “stroke symptom onset” in the most conservative manner, namely the time the patient was last known to be well, many patients whose onsets are unwitnessed are automatically ineligible for thrombolytic therapy even if their true time of onset would make them eligible. Many groups are trying to determine if advanced brain imaging can serve as a substitute “witness” to estimate stroke onset and duration in those patients who do not have a human witness. We review and compare some of these imaging-based approaches to thrombolysis eligbility, which if successful, can potentially expand the use of thrombolytic therapy to a broader stroke patient population.